Biomarkers for early detection of liver cancer: Focus on clinical evaluation by Luk, JM et al.
Title Biomarkers for early detection of liver cancer: Focus on clinicalevaluation
Author(s) Sun, S; Day, PJR; Lee, NP; Luk, JM
Citation Protein And Peptide Letters, 2009, v. 16 n. 5, p. 473-478
Issued Date 2009
URL http://hdl.handle.net/10722/59916
Rights Creative Commons: Attribution 3.0 Hong Kong License
 Protein & Peptide Letters, 2009, 16, 000-000 1 
   0929-8665/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd. 
Biomarkers for Early Detection of Liver Cancer: Focus on Clinical 
Evaluation 
Stella Sun
1,*
, Philip J.R. Day
2
, Nikki P. Lee
1 
and John M. Luk
1
 
1
Department of Surgery, LKS Faculty of Medicine, Jockey Club Clinical Research Centre, The University of Hong 
Kong, Pokfulam, Hong Kong; 
2
Interdisciplinary Molecular Medicine, The Manchester Interdisciplinary Biocentre, Uni-
versity of Manchester, Manchester, UK 
Abstract: This review summarises the screening methods from hepatic ultrasonography to serological biomarkers for 
early detection of liver cancer and focuses on evaluation of biomarkers ability. The development of novel biomarkers ac-
cording to the 5-phase program defined by the Early Detection Research Network (EDRN) is also outlined in this review.  
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INTRODUCTION 
 Metastasis always presents a major challenge before neo-
plasm is finally conquered and once the malignant state is 
acquired, the morbidity and mortality commonly becomes 
high and less likely to benefit from therapeutic intervention 
[1]. The prognosis of different neoplasm, e.g., HCC [2], lung 
[3], ovarian [4] and prostate cancer [5] is poor and has hardly 
improved in recent years, largely owing to the lack of early 
diagnosis, frequent recurrence after surgery and poor surveil-
lance programs.  
 Early detection of cancer ideally helps to decrease the 
mortality rate, resulting in more effective treatment and pro-
longed survival [6]. However, in HCC, prognosis remains 
dismal because of its tumour aggressiveness and the frequent 
association with the common risk factor cirrhosis, which 
renders curative treatment impossible even if it is detected at 
an early stage. The recent practice in HCC and in some neo-
plastic states commonly employed screening regimens for 
early detection. This tool has already been applied in routine 
surveillance for HCC in high risk patients with chronic viral 
hepatitis or cirrhosis. The benefits of early diagnosis have 
prompted research into different methods of screening, 
which include the form of serological biomarkers or radio-
logical tests [7]. Previous studies suggested HCC patients 
acquired better survival when detected by screening for HCC 
in high-risk patients [8]. This review summarises the current 
available screening tools for HCC surveillance both radi-
ologically and serologically, and to evaluate the sensitivity 
and specificity of different biomarkers as the screening 
regimens for early detection of HCC. Finally, it discusses the 
proposed 5-phase programs by the National Cancer Institute 
in order to framework the structure of new biomarkers’ de-
velopment.  
SCREENING BY RADIOLOGICAL IMAGING 
  In carcinogenesis of cirrhotic liver to the development of 
early HCC, different phases from benign regenerative nodule  
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through low-grade dysplastic nodules (LGDN) to high-grade 
dysplastic nodules (HGDN) are commonly observed before 
the final development into overt HCC. Recent advances in 
diagnostic imaging allows early detection of HCC by screen-
ing of high-risk populations [9] and the diagnostic outcome 
is heavily dependent on imaging characteristics. For in-
stance, small HCCs are mostly nodular lesions, large HCCs 
are classified with expansive nodular growth patterns, infil-
trative or diffuse and well-differentiated HCCs often show a 
fibrous capsule. However, limitation on imaging modalities 
presents a problem in the currently used primary radiologic 
screening platforms [10] for small HCC diagnosis. 
 The American Association for the Study of Liver Disease 
(AASLD) has recently recommended that diagnosis of HCC 
can be made if a tumour size larger than 2cm shows typical 
features of HCC in material-enhanced computed tomography 
(CT) or magnetic resonance (MR) imaging [11]. However, 
there is always difficulty in imaging the differentiation of 
precancerous lesions and characterization of hypervascular 
nodules smaller than 2 cm. The context below is a brief 
evaluation of the effectiveness of different imaging modali-
ties (Table 1).  
 Ultrasound (US), computed tomography (CT), as well as 
modern magnetic resonance imaging are the commonly used 
non-invasive, diagnostic imaging techniques for HCC. How-
ever, each of the techniques is limited by a heterogeneous 
sensitivity and specificity. For instance, ultrasound method 
has been shown to have low sensitivity but high specificity 
in revealing HCC in patients who already have a cirrhotic 
liver [12]. Bennett GL’s group demonstrated that the overall 
sensitivity of small lesion tumours is only 20.5%, to a maxi-
mum of 75% for larger lesions of more than 5 cm in size 
[13]. Limitation of the conventional ultrasound could be im-
proved by contrast-enhanced (CE) ultrasonography by using 
ultrasound contrast agents such as perfluorocarbon or sul-
phur hexafluoride.  
 CT and MRI are the other two commonly used diagnostic 
imaging techniques in HCC; their predictive values for 
screening patients with cirrhosis and no known HCC are 
relatively low at around 50% detection sensitivity. In es-
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sence, the diagnosis is often missed in tumours smaller than 
2 cm and those well differentiated tumours [14]. In addition, 
the sensitivity of both CT and MRI are poorly defined for the 
detection of dysplastic nodules in cirrhotic background pa-
tients. 
 Although other contrast enhanced CT and MRI have been 
introduced to characterize the definitive distinction between 
early stage, well-differentiated HCC and borderline lesions, 
there is still a lack of competence in diagnosis of early HCC 
in nodules smaller than 2cm. Diagnosis of HCC may be 
positively established non-invasively by a combination of 
history, physical assessment, blood tests and radiology. 
Therefore, postulation of an alternative screening strategy by 
serological markers is supplement to the routine surveillance 
for HCC.  
SCREENING BY SEROLOGICAL BIOMARKERS 
 New biomarkers are being discovered to identify indi-
viduals at risk of cancer, i.e. for early diagnosis, to determine 
prognosis, to detect recurrence and to monitor treatment 
[15]. Marrero JA et al described that the ideal biomarkers 
should be sensitive, specific, non-invasive, reproducible and 
most importantly enable detection of HCC at an early stage 
[7]. Although early detection is a key step for effective inter-
vention of HCC, the lack of sensitive and specific biomark-
ers is a major reason for the high rate of HCC-related mortal-
ity [16]. Currently, surveillance involves both serological 
testing with serum AFP estimation and ultrasound scanning, 
typically at 6-monthly intervals [17]. Serum biomarkers are 
considered to be the effective method for early detection of 
HCC and compensate for the symptomatic problems associ-
ated with radiological diagnosis. Serological biomarkers 
could be divided into 4 categories: (i) oncofetal antigens and 
glycoprotein antigens; (ii) enzymes and isoenzymes; (iii) 
genes; growth factor and (iv) cytokines [18]. The following 
categories discuss the most widely applied tumour markers 
for single or combinational use in order to improve the effec-
tiveness for screening HCC patients (Table 2).  
ONCOFETAL AND GLYCOPROTEIN ANTIGENS 
 AFP is the most commonly used serum marker for rou-
tine surveillance of HCC, however there are limitations of 
AFP when applied in patients with different etiopathological 
origins. Poor sensitivity and specificity of AFP has been re-
ported in different studies [19] and elevated serum AFP lev-
els are noted in patients with chronic hepatitis C without 
HCC [20]. The reported sensitivity and specificity of AFP 
are 39% to 65% and 65% to 94%, respectively [10]. Moreo-
ver, while AFP may be a useful diagnostic serum marker in 
patients with advanced neoplasm, it has limited utility as a 
screening surveillance in patients with early or small tu-
mours with reduced detection sensitivity [21]. Although the 
conventional marker AFP has limited sensitivity and speci-
ficity, the serum isoforms of AFP based on differential lectin 
binding of the glycan moiety appear to be more effective 
than AFP in differentiating HCC from non-malignant hepa-
topathy and for detecting small HCC tumours. For instance, 
lens culinaris agglutinin – reactive AFP (AFP-L3) is the ma-
jor glycoform of AFP recently reported to be related to the 
progression from moderately differentiated to poorly differ-
entiated HCC [22]. AFP-L3 levels had sensitivities and 
specificities that ranged from 36% to 96% and 89% to 94%, 
respectively. Researchers now attempt to correlate the effi-
cacy of different markers as single or combinational use with 
respect to size and tumour burden. AFP-L3 is commonly 
correlated or compared with levels of AFP and des-gamma-
carboxyprothrombin (DCP). However, a recent report sug-
gested that no improved efficacy was observed by combining 
the two or three markers for HCC diagnosis [23].  
 Golgi protein 73 (GP 73) is another biomarker belonging 
to the glycoprotein antigen group and has recently been 
found to be elevated significantly in HCC patients compared 
to those with cirrhosis. GP73 is an integral membrane pro-
tein localized to the cis Golgi and functions in assisting pro-
teins synthesis and transportation. Proprotein convertase 
mediated cleavage resulting in GP73 secretion [24]. In hu-
man liver tissues, GP73 was expressed in biliary epithelial 
Table 1. Diagnostic Performance of Different Radiological Platforms 
Radiological Imaging  Sensitivity Reference 
CT Overall sensitivity for early HCC detection is 56% Takayasu, K et al 2007 [46] 
MDCT Detection rate for small HCC tumours is 97.5% Zhao, H et al 2007 [47] 
CTA Detection sensitivity of >80% in HCC nodules smaller than 2cm Kim, SR et al 2007 [48] 
US Overall detection sensitivity for HCC is 20.5% and a maximum of 75% for larger 
lesions of more than 5cm in size. 
Benett, GL et al 2002 [13] 
CEUS Sensitivity in the detection of arterial hyperenhancement is 91%. Diagnostic sensi-
tivity of HCC in 2cm nodules or smaller is 52%-91%. 
Gaiani, S et al 2004 [49] 
MRI Sensitivity of 90% in the presence of arterial enhancement. Tumours larger than 
2cm of detection sensitivity >90% whereas in tumours smaller than 2cm is 33% 
El-Serag, HB et al 2008 [50] 
PDG-PET Detection sensitivity of well-differentiated HCC is low, and sensitivity in diagnos-
ing HCC is 55% 
Khan, MA et al 2000 [51] 
Abbreviation used: CT, computed tomography; MDCT, multidetector computed tomography; CTA, CT arteriography; US, ultrasound; CEUS, contrast-enhanced ultrasound; MRI, 
magnetic resonance imaging; PDG-PET, positron-emission-tomography-computed tomography.  
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cells, normal hepatocytes exhibited weak expression signal 
whereas strong expression of GP73 was found in hepatitis 
liver [25]. Exploration by targeted glycoproteomics of hu-
man serum glycoprotein proteome showed GP73 was ele-
vated and hyperfucosylated in animals with HCC. Further-
more, GP73 has demonstrated to be up-regulated in the se-
rum of HCC patients with HBV infected origin, but not in 
HBV or HCV infected individuals. Immunoblots and densi-
tometric quantitation of serum in 353 HCC patients con-
firmed that serum GP73 levels were significantly higher in 
patients with HCC compared to those with cirrhosis, with 
suggested sensitivity of 69% and specificity of 75%. More 
importantly, GP73 levels showed a better sensitivity (62%) 
than AFP (25%) for early detection of HCC [26].  
ENZYMES AND ISOENZYMES 
 Des-? carboxyprothrombin, also known as prothrombin is 
induced by vitamin K absence-II (PIVKA-II), which has 
been reported as a better biomarker than AFP in differentiat-
ing HCC from non-neoplastic state and allows small HCC 
tumour detection [18]. DCP has sensitivities and specificities 
that ranged from 28% to 89% and 87% to 96%, respectively 
[7]. The prevalence of elevated levels of these tumour mark-
ers increase with progression of tumour stage in HCC pa-
tients, also survival was poorer among patients with elevated 
levels of these markers [27]. Recently, PIVKA-II has been 
reported as a useful tumour marker for HCC; complementary 
to AFP, PIVKA-II might be helpful for early diagnosis of 
tumour recurrence [28] and may potentially act as a useful 
indicator of vascular invasion [22]. A report on performance 
characteristics evaluation of AFP, AFP-L3 and DCP sug-
gested that DCP is significantly better than total AFP or 
AFP-L3 in differentiating HCC from cirrhosis. Different 
studies are now under investigation to evaluate the clinical 
usefulness of these biomarkers. There are also studies per-
formed to evaluate the combine use of different markers in 
order to increase the sensitivity and specificity for early HCC 
detection [29, 30].  
GENES  
 Human telomerase reverse transcriptase (hTERT) mRNA 
is a recent candidate, other than a protein, proved to be supe-
rior to AFP and DCP in HCC diagnosis. hTERT mRNA has 
a higher expression in HCC patients’ serum than those with 
chronic liver diseases. hTERT mRNA expression independ-
Table 2. Comparison of the Performance of Single and Combined Diagnostic Markers in HCC 
Serological marker Sensitivity  Specificity Clinical Correlation References 
Single marker performance  
AFP 39%-65% 65%-94% HCC Zinkin, NT et al 2008 [10] 
AFP-L3 36%-96% 89%-94% HCC Marrero, JA et al 2004 [7] 
GP 73 69.0% 75.0% HCC  Marrero, JA et al 2005 [26] 
DCP 28%-89% 87%-96% HCC Marrero, JA et al 2004 [7] 
hTERT 88.2% 70.0% HCV-HCC Miura, N et al 2007 [31] 
GPC3 51.0% 90.0% HCC Hippo, Y et al 2004 [35] 
PIVKA-II 75.1% 94.8% HCC Kim do Y et al 2007 [28] 
AFPIC 39.1% 90.7% Small HCC Giannelli, G et al 2007 [38] 
SCCA 84.2% 48.9% HCC Giannelli, G et al 2005 [29] 
SCCAIC 52.3% 75.7% Small HCC Giannelli, G et al 2007 [38] 
Ang-2 70.6% 73.3% LC-HCC Scholz, A et al 2007 [39] 
IL-6 77.0% 93.0% HCC Porta, C et al 2008 [52] 
Combined markers performance  
AFPIC, SCCA and SCCAIC 57.4% - Small HCC Giannelli, G et al 2007 [38] 
APF and PIVKA-II 40.7% 74.1% Tumour recurrence Kim do, Y et al 2007 [28] 
APF and PIVKA-II 83.3% 77.2% HCC Kim do, Y et al 2007 [28] 
SELDI-TOF MS, AFP, PIVKA-II and 
GP73 75.0% 92.0% HCV-HCC Zinkin, NT et al 2008 [10] 
Glypican 3 and AFP 72.0% 90.0% HCC Hippo, Y et al 2004 [35] 
APF and SCCA 90.8% 44.4% HCC Giannelli, G et al 2005 [29] 
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ently correlated with tumour differentiation. It has been re-
ported that the sensitivity and specificity of hTERT mRNA 
in detecting HCC is 88.2% and 70%, respectively. More im-
portantly, hTERT surpasses AFP and DCP in the diagnosis 
of HCC [31]. AFP mRNA in blood reflects the presence of 
circulating HCC cells and indicates the presence of metasta-
sis. However, AFP mRNA is frequently detected in the 
blood despite only benign liver diseases being present and 
even when patients have no clinical evidence of extrahepatic 
metastases. Therefore, the specificity of the AFP mRNA as 
HCC biomarker and its correlation with the clinical-
pathological parameters of HCC remains controversial [32].  
GROWTH FACTOR AND CYTOKINES 
 The two well-documented biomarkers in this group in-
clude brain-derived neurotrophic factor (BDNF) and glypi-
can-3 (GPC3). Glypican-3, a heparan sulfate proteoglycan, 
plays an important role in cell growth, differentiation and 
migration. Overexpression of GPC3 mRNA and protein has 
been reported in both serum and tissues of early-stage HCC 
but not in normal hepatic tissues [33]. Immunocytochemical 
staining for GPC3 distinguishes HCC from benign and ma-
lignant hepatic lesions and the reported sensitivity and speci-
ficity of glypican-3 in HCC was 90% and 100% respectively 
[34]. In addition, glypican-3 was undetectable in the serum 
of healthy donors and patients with non-malignant liver dis-
ease, whereas in HCC patients glypican-3 was increased to 
53% of HCC patients [33]. Furthermore, GPC3 showed su-
perior sensitivity over AFP in well- or moderately-
differentiated HCC and the combination of these two mark-
ers improved overall sensitivity from 50% to 72% [35]. So 
far, results revealed that glypican-3 is a promising serologi-
cal marker for early detection of HCC. BDNF is a member 
of the nerve growth factor family, over-expression of this 
protein was found to be related to HCC development and 
recurrence [36]. The serum levels of BDNF were positively 
correlated with the platelet counts in HCC patients, suggest-
ing that the interaction between serum BDNF and platelets 
might play an important role in HCC tumour progression 
[37]. However, there has been no report on the sensitivity 
and specificity of this marker for early detection of HCC.  
 Recently, many research groups have reported the differ-
ent combined use of serum biomarkers in clinical practice in 
order to increase the accuracy of HCC diagnosis. For in-
stance, Squamous Cell Carcinoma Antigen (SCCA), a serine 
protease inhibitor physiologically present in the skin, and 
also the immunocomplexed (IC) forms of SCCA and AFP: 
SCCAIC and AFPIC, respectively [38]. In addition, the use 
of angiopoietin-2 in combination with AFP level led to im-
prove discrimination between HCC and cirrhosis. Angio-
poietin-2 (Ang-2) serum levels were found to be elevated in 
patients with liver cirrhosis and HCC, implicating a possible 
role of the angiopoietin-Tie-2 system for neoangiogenesis in 
cirrhosis as well as a marker for the detection of cirrhosis 
and HCC [39].  
 In essence, the positive rate of currently available tumour 
markers can not surpass abdominal ultrasonography (US) as 
modalities to detect small HCC at an early stage, which re-
sults in a possible delay of its diagnosis. Moreover, there is 
always a need to develop more sensitive markers for early 
detection of HCC. Herein, we outline the guidelines for the 
process of new biomarker evaluation and development in a 5 
phase program.  
BIOMARKERS EVALUATION AND DEVELOPMENT 
 The Early Detection Research Network (EDRN) of the 
National Cancer Institute has established a formal framework 
to guide the process of biomarker evaluation and develop-
ment in a 5-phase program [40]. The purpose of the EDRN is 
to framework a guide for biomarker development by coordi-
nating ongoing research on biomarker- screening, biomarker-
validation, clinical repositories and population-screening 
programs in order to promote efficiency and to enhance early 
detection of cancer. Moreover, the screening tool must be 
sufficiently non-invasive and inexpensive to allow wide-
spread applicability. An ideal biomarker should be able to 
detect specifically and non-invasively in tumours but not in 
other non-neoplastic states. As many cancers are heteroge-
neous, especially HCC, it is rare that a single biomarker 
could be used for detection in high specificity and sensitiv-
ity. Therefore, the latest research trend is to apply a panel of 
biomarkers, so as to increase both detection sensitivity and 
specificity.  
 Recent development in microarrays, proteomics and im-
munology offers new approaches to cancer screening [41-
43]. Phase 1- Preclinical Exploratory Studies proposed bio-
marker selection in preclinical studies by identifying charac-
teristics unique to tumour tissues that might give ideas in 
clinical tests for detecting cancer. Thereafter, phase II is en-
tered by performing clinical assay and validation in order to 
identify biomarkers that can distinguish subjects with cancer 
from those without cancer. An important aspect of phase 2 
studies is to identify biomarkers that can detect early-stage 
cancer, therefore, the specimen used for biomarker assay 
must be obtained non-invasively. Inclusion of an adequate 
number of cases in the early stage is important to determine 
the diagnostic capability of the biomarker for early-stage 
cancer [7]. Evaluation on combined use of panels of bio-
markers is always important in this phase. Many currently 
employed biomarkers have been identified in this stage, for 
instance; lens culinaris agglutintin – reactive AFP (AFP-L3) 
and des-gamma carboxyprothrombin (DCP). These have 
been studied extensively and appear to be effective in HCC.  
 Prior to the prospective screening, phase 3-Retrospective 
Longitudinal Repository Studies is carried out as to evaluate 
the capacity of biomarkers to detect preclinical disease. This 
involves the collection of specimens with no clinical diagno-
sis and to determine whether the biomarker can detect cancer 
cases in order to test the capability of pre-clinical disease 
detection. ROC statistical analysis is commonly used in this 
phase to evaluate the performance of a biomarker to identify 
high-risk subjects destined to develop cancer. Markers iden-
tified in this phase include insulin-like growth factor-1 (IGF-
1) [44] and human HGF [45]; however, evaluation of these 
markers has been limited in a few studies. Further evaluation 
will require a long duration of follow-up in a large cohort of 
high-risk subjects for more accurate analysis. The retrospec-
tive phase 3 study determines whether tumours can be de-
tected early before clinical diagnosis. However, no informa-
tion can be identified on the stage and nature of the cancer 
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by the time it is detected. Therefore, phase 4- Prospective 
Screening Studies is established to determine the operating 
characteristics of the biomarkers. Studies at this stage in-
volve individual screening followed by diagnosis and treat-
ment. The final phase addresses whether screening surveil-
lance of high-risk population allows early detection of can-
cer. The formulated five-phase structure ideally enhances the 
generation of more promising and effective biomarkers. 
However, some biomarkers for HCC have still remained in 
phase 1 or 2 studies although they have been reported as 
potential markers for over 15 years. Further progression 
should be performed in biomarker validation and federally 
funded collaborative research networks should be established 
so that promising biomarkers identified in phase 1 and 2 
studies can be evaluated further [7].  
CONCLUDING REMARKS AND FUTURE PERSPEC-
TIVES 
 The existing biomarkers as well as the newly identified 
biomarkers have many limitations regarding their sensitivity 
and specificity. The combinational use of different biomark-
ers may enhance the detection sensitivity for early detection 
of HCC. However, further evaluation and development are 
necessary to enhance the capability of these biomarkers. In 
order to more effectively assess the development of bio-
markers for early detection, the 5 phases program defined by 
the EDRN may help to evaluate and organise biomarker de-
velopment for future validation studies.  
LIST OF ABBREVIATIONS 
HCC = Hepatocellular carcinoma 
CT = Computed tomography 
MRI = Magnetic resonance imaging 
AFP = Alpha fetoprotein 
AFP-L3 = Lens culinaris agglutintin – reactive AFP 
DCP = Des-gamma carboxyprothrombin 
IL-6 = Interleukin 6 
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